Table S3. Receptor and GAG binding site densities

Value / Units / Reference
R1
Abluminal EC / 3,750 / receptors/EC / 1,2
Tumor / 1,100 / receptors/TC / 1,2
R2
Abluminal EC / 300 / receptors/EC / 1,2
Tumor / 550 / receptors/TC / 1,2
N1
Abluminal EC / 20,000 / receptors/EC / †
Tumor / 39,500 / receptors/TC / 1,2
N2
Abluminal EC / 20,000 / receptors/EC
Tumor / 39,500 / receptors/TC / ‡
CD36
Abluminal EC / 1,250 / receptors/EC
Tumor / 2,500 / receptors/TC
CD47
Abluminal EC / 5,000 / receptors/EC
Tumor / 10,000 / receptors/TC
β1 integrin
Abluminal EC / 5,000 / receptors/EC
Tumor / 10,000 / receptors/TC
LRP1
Abluminal EC / 2,500 / receptors/EC
Tumor / 5,000 / receptors/TC
ECM binding density / 0.75 / µM / 3*
EBM binding density / 13 / µM / 4*
PBM binding density / 13 / µM / 4*

EC = endothelial cell; TC = tumor cell; GAG = glycosaminoglycan

† Extrapolated from receptor density on normal ECs, accounting for different cell surface areas ‡ No N2 quantification available; assumed to be the same as N1

Conversions of receptor densities to tissue concentrations:

Abluminal EC receptors: 1.74 × 10-5 (pmol/cm3 tissue)/(receptor/EC);

Tumor receptors: 2.55 × 10-4 (pmol/cm3 tissue)/(receptor/tumor cell)

* Assumed to be the same as FGF

References

1. Finley, S. D., Engel-Stefanini, M. O., Imoukhuede, P. I. & Popel, A. S. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst. Biol. 5, 193 (2011).

2. Imoukhuede, P. I. & Popel, A. S. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med. 3, 225–244 (2014).

3. Bashkin, P. et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28, 1737–1743 (1989).

4. Dowd, C. J., Cooney, C. L. & Nugent, M. A. Heparan Sulfate Mediates bFGF Transport through Basement Membrane by Diffusion with Rapid Reversible Binding. J. Biol. Chem. 274 , 5236–5244 (1999).